Key Indicators of Value & Success in a Life Science Company: What Investors Look For
September 30, 2009
Venture Capital and strategic investors value new and emerging life science companies differently in these challenging times. Entrepreneurs have been forced to modify business plans to stay afloat, while investors have taken a different approach to determining a life science company’s value.
This session will cover long-term strategies that emerging life science businesses should consider when seeking investors, while highlighting opportunities for investors in discovering and creating sustainable value.
-
Diverse perspectives from angel investors to mid-tier funds
-
Issues and perspective from the entrepreneur’s view
-
State of the venture and strategic markets and current trends
-
Factors to be considered in determining the investment opportunities and future returns of life science companies
-
The role of IP in value creation
-
Understanding market opportunities and constraints
Panelists:
-
Gabor Garai, Partner, Foley & Lardner LLP
-
Patrick Heron, General Partner, Frazier Healthcare Ventures
-
Jay S. Kunin, Ph.D., Vice President, TechCoast Angels
-
Bill Molloie, Partner, San Diego Life Sciences Lead, Pricewaterhouse Coopers
-
Hans Petersen, CEO, Traversa Therapeutics
Related Insights
June 11, 2025
Manufacturing Industry Advisor
Foley Automotive Update
Analysis by Julie Dautermann, Competitive Intelligence Analyst Foley is here to help you through all aspects of rethinking your long-term…
June 11, 2025
Energy Current
Leading the Charge: How TVA's SMR Application Signals Industry-Wide Change
On May 20, 2025, the Tennessee Valley Authority (“TVA”) announced that it is the first American utility to submit a small modular reactor…
June 11, 2025
Foley Viewpoints
Stick to the Status Quo: TRO Stops Franchisor from Terminating Franchise Agreement Pending Motion to Transfer
A federal court recently enjoined a franchisor from terminating a franchise agreement or interfering with a franchisee’s operations…